wow-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

Nanzheng
2021-06-18

wow

Low dosage may be behind low efficacy of CureVac vaccine: Study leader

BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa

Low dosage may be behind low efficacy of CureVac vaccine: Study leader

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":168074660,"tweetId":"168074660","gmtCreate":1623945843250,"gmtModify":1703824361244,"author":{"id":3568448901098387,"idStr":"3568448901098387","authorId":3568448901098387,"authorIdStr":"3568448901098387","name":"Nanzheng","avatar":"https://static.tigerbbs.com/1765393aa929f37923e609be5b1a0a65","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>wow</p></body></html>","htmlText":"<html><head></head><body><p>wow</p></body></html>","text":"wow","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/168074660","repostId":2144744636,"repostType":4,"repost":{"id":"2144744636","kind":"news","pubTimestamp":1623940250,"share":"https://www.laohu8.com/m/news/2144744636?lang=&edition=full","pubTime":"2021-06-17 22:30","market":"us","language":"en","title":"Low dosage may be behind low efficacy of CureVac vaccine: Study leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2144744636","media":"The Straits Times","summary":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa","content":"<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Low dosage may be behind low efficacy of CureVac vaccine: Study leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLow dosage may be behind low efficacy of CureVac vaccine: Study leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVAC":"CureVac B.V."},"source_url":"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144744636","content_text":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday (June 17).\nThe German biotech's vaccine proved only 47 per cent effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90 per cent.\nDr Peter Kremsner from the University Hospital in Tuebingen which is running the trial, told Reuters the low efficacy is \"very likely due to the dose\".\nUnlike BioNTech and Moderna, CureVac did not modify the mRNA used in the shots and therefore a higher dosage was not possible because of the side effects to be expected, Dr Kremsner said.\nWith just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively.\nIt is also easy to store and cheaper than the other mRNA shots too.\nThe European Union has agreed to pay 12 euros (S$19.20) per dose for supplies of the shot, an EU internal document shows, but has paid more than 15 euros for the other mRNA shots.\nHowever, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar.\nThe news wiped as much as 52 per cent off the company's value on Thursday.\nCureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.\nDr Kremsner said he thought it was probably a \"long shot\" as to whether CureVac's vaccine might turn out to be more effective when targeting a particular variant.\nThe disappointing results are a blow since European governments had been hoping to add it to their arsenal after age limits were imposed on the use of the Johnson & Johnson and AstraZeneca vaccines due to a link to extremely rare but potentially fatal clotting disorders.","news_type":1},"isVote":1,"tweetType":1,"viewCount":121,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":3,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}